0OCQ Stock Chart & Stats
€0.94
€0.15(22.55%)
At close: 4:00 PM EST
€0.94
€0.15(22.55%)
Day’s Range― - ―
52-Week Range€0.71 - €1.50
Previous CloseN/A
Volume384.00
Average Volume (3M)2.93K
Market Cap
€200.92M
Enterprise Value€108.26
Total Cash (Recent Filing)€92.84M
Total Debt (Recent Filing)€2.18M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield13.26%
Share Statistics
EPS (TTM)-0.17
Shares Outstanding278,559,940
10 Day Avg. Volume1,040
30 Day Avg. Volume2,934
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)282.76
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€7.63M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives Transgene a stronger financial structure than its loss-making operations alone would suggest. Limited debt reduces interest and refinancing pressure, while the sizable equity base provides greater flexibility to continue clinical development and manage funding needs.
Oncology Immunotherapy FocusA focused oncology-immunotherapy strategy can support specialized scientific expertise and concentrated resource allocation across related programs. Its therapeutic vaccines, individualized approaches, and viral-vector candidates give the company multiple ways to pursue immune-based cancer treatment opportunities.
Partnering ModelCollaboration-based development can extend Transgene’s reach beyond its internal resources and provide access to partner capabilities for advancing candidates. This model is structurally relevant for a clinical-stage biotech because partnerships may support development and future commercialization.
Bears Say
Persistent LossesPersistent operating and net losses show that the current business has not yet converted its research platform into sustainable profitability. Deeply negative margins increase dependence on successful clinical progress, partnerships, or new financing to support ongoing operations.
Sustained Cash BurnConsistently negative operating and free cash flow means Transgene consumes cash while advancing its pipeline rather than funding development internally. Continued burn raises reliance on external capital and may constrain the pace or breadth of future research and clinical programs.
Revenue DeteriorationThe sharp revenue decline and high volatility indicate that current income is not a dependable foundation for the operating cost base. Without a clear sustainable top-line trajectory, future funding capacity remains closely tied to collaborations, milestones, or other external support.
Transgene News
0OCQ FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest share price was €0.70 and its highest was €1.50 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €200.92M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Nov 09, 2026 which is in 38 days.
How were Transgene SA’s earnings last quarter?
Transgene SA released its earnings results on Sep 24, 2026. The company reported -€0.057 earnings per share for the quarter.
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of 13.26%. See more information on Transgene SA dividends here
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 278,559,940 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Transgene SA reported an EPS of -€0.057 in its last earnings report. Following the earnings report the stock price went down -5.14%.
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in GB:0OCQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―